微小RNA与宫颈癌  

MicroRNA and cervical cancer

作　　者：熊焱强[1] 王玎[1] 李志英[1] 

机构地区：[1]三峡大学仁和医院妇产科,宜昌443002

出　　处：《生命科学》2016年第4期470-474,共5页Chinese Bulletin of Life Sciences

基　　金：湖北省教育厅科研计划项目(D20151202);三峡大学研究生创新基金项目(2015CX101)

摘　　要：微小RNA(microRNA,miRNA)在宫颈癌的发生、侵袭、转移和复发等过程中扮演重要角色,与其预后密切相关。它能在组织、血清和血浆等标本中稳定存在,可通过调控靶基因从而促进宫颈癌细胞凋亡,并能改变宫颈癌细胞对药物和射线的敏感性,这使得mi RNA有望成为一种与宫颈癌诊疗密切相关的新型分子标志物。就miRNA在宫颈癌的早期分子诊断、治疗以及预后判断等方面的最新研究进展作一综述。microRNA （miRNA） plays an important role in the occurrence, invasion, metastasis and recurrence of cervical cancer, which is closely related to the prognosis of cervical cancer. MiRNAs can not only exist stably in tissue, serum and plasma, but also promote cervical cancer cell apoptosis and change drug and radiation sensitivity of cervical cancer cell line through regulating target genes. Since miRNA is closely related to cervical cancer diagnosis and treatment, it is expected to be a new kind of molecular marker. This article reviews the latest research progress in molecular diagnosis, treatment and prognosis of miRNAs in the early stage of cervical cancer.

关 键 词：微小RNA 宫颈癌 诊断 治疗 预后 

分 类 号：Q522[生物学—生物化学] R737.33[医药卫生—肿瘤]